Tuesday, November 05, 2024
name of Prensa Latina
Bandera inglesa
English Edition
Search
Close this search box.
name of Prensa Latina

NEWS

NEWS

Monoclonal treatments combo reduces Covid-19 hospitalizations

Washington, Sep 1 (Prensa Latina) In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab ― two monoclonal antibody treatments under Food and Drug Administration emergency use authorization ― keep high-risk patients out of the hospital when infected with mild to moderate Covid-19, according to The Lancet´s EClinicalMedicine.

Experts were able to check that once treatment was applied, the numbers of Covid-19 people hospitalized were significantly lower, and the ICU admission and mortality rates also went down.

‘Our overall conclusion at this point is that monoclonal antibodies are an important treatment option in treatment to reduce the impact of Covid-19 in high-risk patients,’ researchers said.

Other scientific studies found skepticism about this combination and suggested that casirivimab should never be administered without mixing it with imdevimab.

The Regen-Cov combination is injected into a vein slowly over at least one hour, so patient will need to be monitored for a short time to make sure he does not have an allergic reaction.

It is usually given as a one-dose as soon as possible after testing positive for Covid-19, or within 10 days after the onset of symptoms. Patient treated with Regen-Cov will not be less contagious for other people.

The patient should continue with self-care measures such as self-isolation, social distancing, hand-washing, wear of masks, disinfect surfaces and not share personal items with others.

Regen-Cov – which is lethal for pregnant women – also cannot prevent you from being infected with coronavirus again.

mh/Pll/msm / joe/cvl

LATEST NEWS
RELATED